Abstract Details

Title NfL Levels in CSF, Serum, and Plasma of RRMS and PPMS Patients in a Cross-sectional UCSF Cohort

Topic Multiple Sclerosis

Presentation(s) P2 - Poster Session 2 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-082

Objective

To present correlations between neurofilament light chain (NfL) levels in cerebrospinal fluid (CSF), serum or plasma, with MRI disease activity, in predominantly naïve-to disease modifying treatment RRMS and PPMS patients.

Background

Highly sensitive assay technologies, namely the Quanterix SIMOA platform, enables accurate and precise measurements of the neuronal-axonal injury biomarker NfL in the blood of MS patients, and has driven interest in the use of NfL as a peripheral biomarker of neuronal injury status in MS.

Design/Methods

Matching CSF, serum, and plasma samples from a cross-sectional, single-site (UCSF) cohort of RRMS (N=90), and PPMS (N=17) patients were assayed for NfL utilizing qualified versions of the Quanterix NfL Advantage Kit ™ on the SIMOA platform for all three matrices. Correlations were made between NfL levels and MRI findings and/or type of MS.

Results CSF, serum, or plasma levels of NfL levels were not significantly different between RRMS and PPMS. RRMS CSF and peripheral blood (serum or plasma) NfL levels correlated strongly, however correlation was driven mainly by patients with high NfL levels. PPMS serum or plasma levels did not correlate with PPMS CSF levels. RRMS patients with >1 enhancing T1 brain lesion had significantly higher levels of CSF levels of NfL than RRMS patients with <1. RRMS CSF, serum, and plasma levels weakly correlated with EDSS, T1 and T2 lesion number. In contrast PPMS CSF NfL , but not serum, or plasma NfL correlated with T1 and T2 lesion number.

Conclusions

In RRMS, serum and plasma levels of NfL serve well as surrogates for CSF NfL and may be useful surrogates of MRI disease activity. PPMS CSF NfL levels may be a useful surrogate of MRI activity, however peripheral levels of NfL in PPMS may not serve well as a surrogate for CSF NfL levels.

Authors/Disclosures
Christopher Harp PRESENTER	Christopher Harp has received personal compensation for serving as an employee of Genentech. Christopher Harp has received stock or an ownership interest from Genentech, Inc..
Xiaoye Ma	Xiaoye Ma has received personal compensation for serving as an employee of Genentech.
Robert Hendricks	No disclosure on file
	No disclosure on file
	No disclosure on file
H.-Christian C. von Büdingen, MD, FAAN (F. Hoffmann-La Roche Ltd)	Dr. von Büdingen has received personal compensation for serving as an employee of F. Hoffmann-La Roche Ltd. Dr. von Büdingen has stock in F. Hoffmann-La Roche Ltd.
	No disclosure on file
Ann Herman	Ann Herman has received personal compensation for serving as an employee of Genentech, Inc. Ann Herman has received stock or an ownership interest from F. Hoffman-La Roche Ltd.

��ɫ��

��ɫ��